Xiaojun Liu

Dr. Xiaojun Liu


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2020 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
ZSZiqian Sun
Ziqian Sun
SGShouyang Gao
Shouyang Gao
LXLili Xuan
Lili Xuan
XLXiaojun Liu
Xiaojun Liu
Emerging studies have revealed the critical role of long non‐coding RNAs (lncRNAs) in epithelial ovarian cancer (EOC) development and progression. Till now, the roles and potential mechanisms regarding FEZF1 antisense RNA 1 (FEZF1‐AS1) within ovarian cancer (OC) remain unclear. The objective of this study was to uncover the biological function and the underlying mechanism of LncRNA FEZF1‐AS1 in OC progression. FEZF1‐AS1 expression levels were studied in cell lines and tissues of human ovarian cancer. In vitro studies were performed to evaluate the impact of FEZF1‐AS1 knock‐down on the proliferation, invasion, migration and apoptosis of OC cells. Interactions of FEZF1‐AS1 and its target genes were identified by luciferase reporter assays. Our data showed overexpression of FEZF1‐AS1 in OC cell lines and tissues. Cell migration, proliferation, invasion, wound healing and colony formation were suppressed by silencing of FEZF1‐AS1. In contrast, cell apoptosis was promoted by FEZF1‐AS1 knock‐down in vitro. Furthermore, online bioinformatics analysis and tools suggested that FEZF1‐AS1 directly bound to miR‐130a‐5p and suppressed its expression. Moreover, the inhibitory effects of miR‐130a‐5p on the OC cell growth were reversed by FEZF1‐AS1 overexpression, which was associated with the increase in SOX4 expression. In conclusion, our results revealed that FEZF1‐AS1 promoted the metastasis and proliferation of OC cells by targeting miR‐130a‐5p and its downstream SOX4 expression.

1 January 2021 in Technology in Cancer Research & Treatment
Verified
Journal Article
Open access
PDF file
QZQiang Zhang
Qiang Zhang
XLXiaojun Liu
Xiaojun Liu
YLYang Li
Yang Li
XYXiao-Wei Ying
Xiao-Wei Ying
LCLu Chen
Lu Chen
LncRNA SET-binding factor 2 (SBF2) antisense RNA1 (SBF2-AS1) has been proven to play an oncogenic role in various types of tumors, but the prognostic role of SBF2-AS1 in tumors, especially in diffuse lower-grade glioma (LGG), is still unclear. Here, we aimed to investigate the prognostic value of SBF2-AS1 in LGG. The LGG expression profiles from The Cancer Genome Atlas (TCGA, n = 524) and Chinese Glioma Genome Atlas (CGGA, n = 431) were mined by Kaplan-Meier analysis, Cox regression analysis, Chi-square test and GSEA analysis. Through Kaplan-Meier analysis, we found the prognosis of LGG patients with high expression of SBF2-AS1 were worse than that of patients with low expression (Log Rank P < 0.001). Cox analysis showed SBF2-AS1 was an independent prognostic factor for poorer overall survival in LGG (P < 0.05). SBF2-AS1 was found to be significantly related to IDH mutation status and SBF2-AS1 was highly expressed in IDH wildtype group. GSEA analysis obtained a total of 126 GO terms and 6 KEGG pathways that were significantly enriched in SBF2-AS1 high expression phenotype (NOM P value < 0.05). We found these 126 GO terms and KEGG pathways were mainly related to immunity. In conclusion, lncRNA SBF2-AS1 expression is an immune-related lncRNA associated with unfavorable overall survival in LGG. SBF2-AS1 could be a reliable prognostic biomarker for patients with LGG.